Synthetic Pyrethroid (Antiparasitic)
Pregnancy: Compatible — safe to use in pregnancy
Permethrin
Brand names: Lyclear (5% cream)
Adult dose
Dose: Scabies: 5% cream applied to entire body surface from neck down (including scalp/face in elderly/immunocompromised), left on for 8–12h, then washed off. Repeat after 7 days.
Route: Topical
Frequency: 2 applications, 7 days apart
Max: Single tube per application for adults
All household contacts must be treated simultaneously. Wash and hot-tumble-dry clothing and bedding on treatment day. Treat any itch that persists >4 weeks post-treatment with crotamiton (not another course of permethrin).
Paediatric dose
Route: Topical
Frequency: 2 applications, 7 days apart
Max: Age-appropriate amount
Concentration: 5% cream Cream/ml
Children ≥2 months: apply to entire body surface including face, scalp, and ears. Avoid eyes and mouth. Children <2 months: seek specialist advice.
Dose adjustments
Renal
N/A
Hepatic
N/A
Clinical pearls
- Post-scabies itch: continues for 4–6 weeks after successful treatment (dead mite body parts cause ongoing immune reaction) — treat with crotamiton cream or antihistamines; do NOT retreat early
- Treat all contacts simultaneously — even asymptomatic contacts
- Crusted (Norwegian) scabies: requires oral ivermectin + topical permethrin under specialist supervision
- Malathion 0.5% alcoholic lotion: alternative to permethrin if first-line fails
Contraindications
- Age <2 months
- Hypersensitivity to pyrethrins
Side effects
- Skin irritation and burning (first application)
- Transient worsening of itch (post-scabies itch is common for 4 weeks after treatment)
- Contact sensitisation (rare)
Interactions
- None significant
Monitoring
- Symptom resolution at 4 weeks
- Identification and treatment of contacts
- Persistence of itch (distinguish treatment failure from post-scabies itch)
Reference: BNFc; BNF; NICE NG225; PHE Scabies Guidance. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD